Replies to post #2244 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Thanks Dew. The second to last slide (#29) lists the key catalysts for 2022. One of them is to select a third mechanism for combination regimen with EDP-514 for HepB treatment. I will feel better when the candidate(s) are announced and into trials.